This surgical procedure represents an advancement in dermatologic treatment, combining precision tissue removal with comprehensive management strategies for optimal patient outcomes.

Overview and Clinical Significance

This procedure addresses a common dermatologic concern that affects many patients. The technique has been refined over decades of clinical practice and continues to evolve with advances in technology and surgical methodology. Modern approaches emphasize tissue conservation, excellent cosmetic outcomes, and minimal complications.

Patient Selection and Indications

Appropriate patient selection is critical for optimal outcomes. Candidates should have clear medical indication for intervention, realistic expectations about results, and commitment to post-operative care. Contraindications include active infection, severe immunosuppression in certain cases, and uncorrected bleeding disorders.

Pre-operative Evaluation

Comprehensive pre-operative assessment includes medical history review, physical examination, photography for documentation, and discussion of risks, benefits, and alternatives. Patients on anticoagulants may require bridging protocols or medication adjustment. Previous allergic reactions to anesthetics must be documented.

Anesthetic Technique

Local anesthesia with 1% lidocaine and 1:100,000 epinephrine is standard. This provides rapid onset (5-10 minutes), excellent hemostasis through vasoconstriction, and safe dosing up to 10-12 mg/kg with epinephrine. Regional nerve blocks may be used for specific anatomic locations to improve hemostasis and reduce tissue distortion. Field block technique (injection around rather than into the lesion) prevents contamination and provides optimal anesthesia.

Surgical Technique

The procedure begins with sterile preparation of the surgical field using antiseptic solution (4% chlorhexidine or 10% povidone-iodine). Proper positioning ensures adequate exposure and patient comfort. The surgeon uses meticulous technique with appropriate instruments, maintaining hemostasis throughout to ensure clear visualization of the surgical field.

Careful tissue handling preserves tissue viability and minimizes trauma. The specimen is oriented properly and marked with sutures or dyes to enable accurate histopathologic examination. Proper technique throughout ensures optimal margin assessment if required.

Hemostasis Methods

Several techniques maintain excellent hemostasis:

  • Epinephrine-soaked gauze: Most common, applied for 2-3 minutes
  • Electrocautery: Used carefully to avoid tissue artifact that obscures margins
  • Suture ligation: For significant bleeding vessels
  • Topical hemostatic agents: Thrombin, gelatin sponge, or microfibrillar collagen for persistent oozing

Wound Closure Options

The method of wound closure depends on defect size and location. Small defects (<1 cm) typically heal by primary intention after simple suturing. Moderate defects (1-3 cm) may use local flaps for optimal cosmetic outcome. Large defects (>3 cm) may require skin grafting. The surgeon selects the technique that optimizes both functional and cosmetic outcomes.

Reconstruction Techniques

Primary Closure

Direct suturing of wound margins provides the best cosmetic outcome for small defects. Simple interrupted or running subcuticular sutures are used. Minimal tension reduces scar width and improves final appearance.

Local Flap Reconstruction

For moderate defects, local flaps provide excellent color and texture match:

  • Advancement flap: Tissue advanced from one direction
  • Rotation flap: Tissue rotated from adjacent area
  • Bilobed flap: Two tissue lobes for larger defects
  • Rhombic (Limberg) flap: Preferred for certain geometric defects
  • O-to-Z flap: Converts circular defects to elliptical pattern
  • V-Y advancement: Excellent for midline defects

Skin Graft Reconstruction

When local tissue is inadequate, skin grafting provides coverage:

  • Full-thickness skin graft (FTSG): 0.015-0.025 inch thick, includes epidermis and dermis. Donor sites: preauricular, supraclavicular, inner arm. Excellent cosmetic outcome with minimal contraction.
  • Split-thickness skin graft (STSG): 0.010-0.015 inch thick. For larger defects or compromised blood supply. More contraction than FTSG but broader donor site availability.

Secondary Intention Healing

Selected wounds on trunk or areas where scarring is less visible allowed to epithelialize and contract naturally over 4-8 weeks. Provides excellent results in appropriate locations with minimal surgical intervention.

Post-operative Wound Management

Immediate Post-operative (Days 1-3)

  • Pain management with over-the-counter analgesics
  • Elevation to reduce swelling
  • Light pressure dressing if needed for oozing
  • Antibiotic ointment application twice daily
  • Nonadhesive dressings prevent trauma to healing tissue

First Two Weeks

  • Gentle cleansing with mild soap and cool water daily
  • Continued antibiotic ointment application
  • Suture removal on appropriate schedule (face 5-7 days, trunk/extremities 7-10 days, legs 14 days)
  • Activity restriction: avoid heavy lifting, strenuous exercise, swimming
  • Avoid picking at healing tissue or forcing off scabs

Weeks 3-12: Scar Maturation

  • Continued sun protection with SPF 30+ for at least 3 months
  • Gentle massage of scar (2-3 weeks after suture removal) helps remodel collagen
  • Silicone gel sheets worn 12+ hours daily may flatten and fade scars
  • Monitor for signs of abnormal scar formation (hypertrophic, keloid)

Expected Healing Timeline

  • Days 1-7: Inflammation phase, initial bleeding controlled, mild swelling and bruising
  • Days 8-14: Proliferative phase begins, pink/red scar formation, sutures removed
  • Weeks 3-6: Continued scar redness, gradual softening of induration
  • Months 2-3: Scar fades toward white/flesh tone, becomes flatter
  • Months 3-12: Final maturation, scar nearly invisible in many cases
  • Beyond 12 months: Minimal further change; revision options if needed

Complications and Management

Infection (1-2%)

Usually managed with topical or oral antibiotics. Signs include increasing redness, warmth, purulent drainage, or fever. Contact surgeon if infection suspected.

Bleeding (1-3%)

Mild oozing normal in first 24 hours. Persistent or heavy bleeding requires immediate attention and possibly re-exploration.

Hypertrophic Scarring (5-10%)

More common on chest, shoulders. Prevention includes tension reduction, sun protection. Treatment options: steroid injection, silicone therapy, laser scar revision, surgical revision.

Keloid Formation (rare)

More common in darker-skinned patients. May require dermatologist intervention with steroid injection, silicone therapy, or other treatments.

Nerve Injury (<1%)

Risk increases with large lesions on extremities. Most resolve spontaneously within weeks to months.

Seroma Formation

Fluid collection under the skin. May resolve spontaneously or require aspiration if persistent.

Activity Return Timeline

  • Light activity (desk work): 24-48 hours
  • Walking: 1 week
  • Moderate exercise (jogging, cycling): 2 weeks
  • Heavy exercise (weight training, contact sports): 3-4 weeks
  • Swimming: After sutures removed and incision closed (7-10 days)
  • Hot tubs/saunas: After incision fully closed

Specialized Considerations

Facial Surgery

On the face, cosmetic outcome is paramount. Minimal tension, proper vector alignment, and careful wound closure optimize results. Smaller sutures (5-0 or 6-0) reduce track marks. Suture removal earlier (5 days) prevents these marks.

High-Tension Areas

Chest, shoulders, and back are prone to hypertrophic scarring. Tension reduction with wide undermining and layered closure minimizes scar width.

Anatomically Challenging Areas

Periorbital, perioral, and ear surgery requires specialized knowledge of anatomy and reconstruction options. Expertise in regional flaps essential for optimal function and cosmesis.

Scar Revision Options

If scar remains problematic at 12 months post-surgery, options include:

  • Dermabrasion: Smooths surface irregularities; performed 8-12 weeks post-surgery
  • Laser scar revision: Fractionated lasers smooth irregularities and reduce redness
  • Steroid injection: For hypertrophic scars; multiple treatments may be needed
  • Chemical peel: For surface irregularities and discoloration
  • Z-plasty or other geometric revision: Changes scar direction to better align with natural skin creases
  • Full-thickness excision and re-closure: For problematic scars that warrant complete revision

Patient Education and Expectations

Clear communication about realistic expectations optimizes patient satisfaction. Most patients achieve excellent cosmetic results with proper post-operative care. Scars mature over 12-18 months and continue to improve during this time. Early appearance should not cause alarm; final scar visibility typically much better than appearance in first weeks.

Conclusion

Modern surgical techniques combined with meticulous post-operative care provide excellent cosmetic and functional outcomes. Success depends on proper patient selection, technical expertise, and patient commitment to post-operative instructions. Consultation with a board-certified dermatologic surgeon ensures optimal results for your specific situation. Most patients experience high satisfaction with minimal complications when care is optimized.

References

  1. Singer AJ, Dagum AB. Current management of acute cutaneous wounds. N Engl J Med. 2008;359(10):1037-1046.
  2. Mustoe TA, O'Shaughnessy BA, Klemenich J. Chronic wound healing: re-thinking the approach. Plast Reconstr Surg. 2006;117(7 Suppl):177S-188S.
  3. Tredget EE, Shankowsky HA. Scar management. Adv Wound Care. 1998;11(6):319-329.
  4. Aarabi S, Longaker MT, Gurtner GC. Hypertrophic scar formation: new approaches to treatment. PLoS Med. 2007;4(8):e234.
  5. Gold MH. Silicone gel, ointments, and occlusive dressings in managing hypertrophic scars. Semin Cutan Med Surg. 2000;19(4):272-277.
  6. Pollack SV. Wound healing and management. Dermatol Clin. 1989;7(3):639-648.
  7. Breuninger H, Schaumburg-Lever G. Excisional treatment of basal cell carcinoma. Dermatol Surg. 2003;29(4):321-326.
  8. Connolly SM, et al. AAD/ACMS/ASDSA/ASMS appropriate use criteria. J Am Acad Dermatol. 2012;67(4):531-550.